ASH: Novartis’s Ianalumab Has Disease-Modifying Potential In ITP

Longer-Term Disease Control With Just Four Infusions

 
• By Mandy Jackson
  
Investigator Hanny Al-Samkari, Harvard Medical School and Mass General Brigham (Alaric DeArment)

More from Clinical Trials

More from R&D